February 2026

Issue Contents

  • Newly Activated Studies


  • Accruals, Biospecimens, & Special Entries


  • All About AYAs


  • CCDR Corner


  • Diving In


  • Smiling Faces

Newly Activated Studies


These studies have recently activated.

More information can be found on CTSU.


  • SN2426: A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
  • EA6232: A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients with Multiple Atypical Nevi and a Prior History of Melanoma

Research Base Meetings



SWOG Spring Meeting: April 30-May 2, 2026-San Francisco, CA

ECOG-ACRIN Spring Meeting: May 5-7, 2026- Baltimore, MD

Alliance Spring Meeting: May 13-15, 2026 - Chicago, IL


Monthly Coordinator Call

Affiliate Site Staff Meeting (Coordinator Call)


Monthly Coordinator Meeting

Thursday, February 26, 2026


The meeting will be held from

2:00PM - 3:00PM

on Microsoft Teams


If you did not receive a recurring Teams calendar invite for these meetings, please reach out to Jessica Michael, jmichael@gibbscc.org.


The link for the next call is below

Accruals, Biospecimens, & Special Entries

Under-Represented Populations

All About AYAs

CCDR Corner

Diving In!

February is American Heart Month, a national annual observance that raises awareness of cardiovascular disease – the leading cause of death in the US – and promotes lifesaving, healthy habits. With cancer being the second leading cause of death in the US, and considering cancer patients have two to six times higher risk of dying from cardiovascular disease (CVD) than the general population (Florido et al., 2022), it is important to highlight key connections between cancer and heart health due to the shared risk factors among both illnesses such as smoking, obesity, and chronic inflammation.


Researchers at the American Cancer Society have found that, as cancer patients survive longer due to advancements in cancer treatment, cancer survivors face a 42% greater risk of developing heart issues such as heart failure or stroke, indicating that cancer patients have a higher risk of mortality related to cardiac issues rather than the cancer treatment itself. For example, data from a population-based observational study of CVD mortality risk in US cancer patients showed certain chemotherapy drugs, targeted therapies/immunotherapies, and radiation to the chest can damage heart muscle (cardiotoxicity), increase heart rates, or cause inflammation (pericarditis) (Sturgeon et al., 2019).


The American Heart Association and the American Cancer Society emphasize the importance of protecting your heart during cancer treatment, whether you are still in active treatment, recently completed treatment, or are a long-term survivor, by following the tips below:


·        Maintain a healthy weight

·        Get regular exercise

·        Eat a healthy diet, with emphasis on fruits, vegetables and whole grains

·        Get recommended cancer screenings

·        Creating a survivorship care plan

·        Keep your follow-up appointments

·        Take care of your emotional health

Smiling Faces

We’re proud to recognize Dr. Michael Humeniuk and our oncology research team for their contributions to the recently reported A222001 clinical trial, now published in the Journal of Clinical Oncology.  The trial showed that men with prostate cancer had a significant reduction in hot flashes when treated with oxybutynin. This pivotal study represents an important advance in prostate cancer, survivorship care and side-effect management, reflecting our continued commitment to improving cancer care through research and collaboration. Congratulations to Dr. Humeniuk and all investigators for their leadership and dedication in shaping the future of oncology care! 

Click below to read the full publication!

We would also like to congratulate Dr. Humeniuk for being recognized as the Top CCDR Accruing Investigator for his work on the WF-2301CD study, highlighted in the Wake Forest Quarterly Newsletter for February 2026. Congratulations, Dr. Humeniuk!

Lauren Kaczynski has joined the team as a Clinical Research Coordinator! Lauren graduated with a BS in Biology from the University of Georgia and obtained her BSN from Kennesaw State University. Prior to this role, she worked as a nurse in critical care, mostly in the Philadelphia area. Welcome to the team, Lauren!

Do you have any staff you would like highlighted in The Connector?

Please submit it by the 15th of the month to Keira: kvanzyl@gibbscc.org




Connect with us on LinkedIn!

Administrator

Kamara Mertz-Rivera, MA, CCRC

Email: UpstateNCORP@srhs.com

Phone: 864-560-6104


CCDR Director

Melyssa Foust, MSN, RN, OCN

Email: UpstateNCORPCCDR@srhs.com

Phone: 864-560-1035


Regulatory

Josh Acuna, MPH

Email: UpstateNCORPRegulatory@srhs.com

Phone: 864-530-6523



Grant Manager

Alex Akkary, MBA

Email: UpstateNCORPFinance@srhs.com

Phone: 864-560-6967


Quality Assurance

Jessica Michael

Email: UpstateNCORPQA@srhs.com

Phone: 864-530-6510


Community & Social Media 

Keira van Zyl, BA, BS

Email: kvanzyl@gibbscc.org

Phone: 864-560-1956

2759 Hwy 14 South • Greer • SC • 29651